Cannara Biotech (LOVE) investor relations material

Company overview and operations

• Operates two major facilities in Quebec: a 625,000 sq ft indoor site and a 1 million sq ft hybrid greenhouse, both acquired at significant discounts to construction cost.

• Achieves profitability and positive free cash flow, distinguishing itself among Canadian cannabis producers.

• Current production run rate is 50,000 kg per year, with the ability to double capacity organically using existing infrastructure.

• Farnham facility also generates $4 million annually from non-cannabis tenants, reinvested into business growth.

• Valleyfield facility is 50% activated, with 12 of 24 rooms operational, targeting 100,000 kg annual output and $300 million net revenue at full scale.

Leadership and team

• CFO has a hands-on role, overseeing finance, product creation, branding, and sales, leveraging a comprehensive understanding of the business.

• CEO is highly involved, serving as master grower and developing all SOPs, with a background in IT and entrepreneurship.

• Executive team includes a CTO who built proprietary IT systems for automated cultivation.

• Key investors and board members provide access to capital and strategic guidance.

Competitive advantages and market positioning

• Focus on genetics and in-house R&D, investing in phenol hunts to ensure facility-specific success and product differentiation.

• State-of-the-art assets acquired at a fraction of their build cost, with operations in Quebec benefiting from low electricity and labor costs.

• Three brands drive over $100 million in revenue, with two main brands accounting for the majority.

• Quebec's unique regulatory environment fosters brand loyalty due to marketing restrictions and limited retail locations.

• Holds 13% market share in Quebec (second largest), with national expansion focused on measured growth.